

Special Issue

New Technologies in Prostate Cancer: From Diagnosis to Treatment

Message from the Guest Editor

This Special Issue aims to explore cutting-edge, new technologies that may, in the near future, be able to change the current diagnostic and treatment pathways of prostate cancer. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

Artificial intelligence;

Radiomics;

PET/MRI;

New PET tracers;

Liquid biopsy;

New genomic markers;

Telemedicine;

Augmented reality;

New and developing robotic systems;

Single-site surgery;

Telerobotic surgery;

Radio-guided surgery;

Focal therapies;

Theranostics.

Guest Editor

Dr. Fabio Zattoni

1. Department of Urology, Azienda Ospedale-Università Padova, 35122 Padova, Italy

2. Department of Medicine (DIMED), University of Padua, 35128 Padua, Italy

Deadline for manuscript submissions

closed (31 July 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/86867

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)